Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail

The mechanistic action of bromodomain-containing protein 4 (BRD4) in cancer motility, including epithelial-mesenchymal transition (EMT), remains largely undefined. We found that targeted inhibition of BRD4 reduces migration, invasion, in vivo growth of patient-derived xenograft (PDX), and lung colonization of breast cancer (BC) cells. Inhibition of BRD4 rapidly decreases the expression of Snail, a powerful EMT transcription factor (EMT-TF), via diminishing its protein stability and transcription. Protein kinase D1 (PRKD1) is responsible for BRD4-regulated Snail protein stability by triggering phosphorylation at Ser 11 of Snail and then inducing proteasome-mediated degradation. BRD4 inhibition also suppresses the expression of Glil, a key transductor of Hedgehog (Hh) required to activate the transcription of SNAIL, in BC cells. The GACCACC sequence (-341 to -333) in the SNAI1 promoter is responsible for Glil-induced transcription of SNAIl. Clinically, BRD4 and Snail levels are increased in lung-metastasized, estrogen receptor-negative (ER-), and progesterone receptor-negative (PR-) breast cancers and correlate with the expression of mesenchymal markers. Collectively, BRD4 can regulate malignancy of breast cancer cells via both transcriptional and post-translational regulation of Snail.